“Both of the grants I lost were trying to answer some really fundamental questions about how the spread of cancer works.”On “The Weekend Intelligence”, how science became collateral damage in the war between Donald Trump and universities https://t.co/iifQFq8vHy ...

Core Insights - Alphon Capital is leveraging blockchain technology to fund cancer research through asset tokenization, aiming to merge digital assets with biotech innovations [1][7][10] - The integration of blockchain is seen as a way to accelerate funding for biotech projects, particularly in the context of cancer research, which traditionally faces funding challenges [9][10][15] Company Overview - Alphon Capital focuses on the Telegram ecosystem, which has over a billion users, and aims to create revenue-generating businesses within this space [2][18] - The company is a rebrand of Portage Biotech and is involved in developing novel cancer therapies, with one molecule already in phase one clinical trials [7][8] Blockchain Integration - The positive shift in US regulations is driving institutional adoption of blockchain technologies, with companies like Telegram leading the way [4][5] - Tokenization is expected to revolutionize funding mechanisms for biotech, allowing for quicker capital raises compared to traditional methods [10][12] Financial and Scientific Goals - Alphon aims to be a growth vehicle for various revenue-producing businesses across the Telegram ecosystem, including gaming, DeFi, and healthcare applications [17][18] - The company has invested in a large treasury of Ton tokens to strengthen its balance sheet and create demand for the token within its business model [19]